Xuejun Sun

13PUBLICATIONS
12CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 13, 2026
CDX2 confers ferroptosis resistance in stage II-III colon cancer via upregulation of NUPR1.

Junhui Yu, Mingchao Mu, Chenye Zhao

|Jun 02, 2025
Multiomics-Driven Drug-Cell Interaction Network for Chemotherapy Sensitivity Prediction in Metabolically Defined Triple-Negative Breast Cancer Subtypes.

|Oct 10, 2023
USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A.

Mingchao Mu, Qin Zhang, Jing Li

|Aug 09, 2023
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.

Mingchao Mu, Qin Zhang, Chenye Zhao

|Feb 10, 2023
Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.

Junhui Yu, Kui Yang, Jianbao Zheng

|Apr 22, 2022
Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.

Junhui Yu, Kui Yang, Jianbao Zheng

Pageof 3

Frequent Collaborators

3 joint publications

Junhui Yu

2 joint publications

Yunhua Wu

2 joint publications

Xuqi Li

2 joint publications

Jie Xia